Recursion Cash vs Total Liab Analysis

RXRX Stock

USD 7.01 0.34 5.10%

Recursion Pharmaceuticals financial indicator trend analysis is much more than just breaking down Recursion Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Recursion Pharmaceuticals is a good investment. Please check the relationship between Recursion Pharmaceuticals Cash and its Total Liab accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Recursion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.

Cash vs Total Liab

Cash vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Recursion Pharmaceuticals Cash account and Total Liab. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Recursion Pharmaceuticals' Cash and Total Liab is -0.05. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Total Liab in the same time period over historical financial statements of Recursion Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Recursion Pharmaceuticals' Cash and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of Recursion Pharmaceuticals are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Cash i.e., Recursion Pharmaceuticals' Cash and Total Liab go up and down completely randomly.

Correlation Coefficient

-0.05

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Cash

Cash refers to the most liquid asset of Recursion Pharmaceuticals, which is listed under current asset account on Recursion Pharmaceuticals balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Recursion Pharmaceuticals customers. The amounts must be unrestricted with restricted cash listed in a different Recursion Pharmaceuticals account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Recursion Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Recursion Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Recursion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.At this time, Recursion Pharmaceuticals' Issuance Of Capital Stock is fairly stable compared to the past year. Enterprise Value is likely to rise to about 1.9 B in 2024, whereas Selling General Administrative is likely to drop slightly above 64.7 M in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	8.4M	11.8M	32.5M	34.1M
Interest Income	73K	6.3M	18.3M	19.2M

Depreciation And Amortization Interest Income

Recursion Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital
Total Assets		0.76	0.97	0.96	0.95	0.84	0.94	0.94	-0.96	-0.88	0.94	0.96	0.83	0.65	0.62	-0.98	0.98	0.78	0.73	-0.53	0.86	-0.86	0.76	0.86	-0.25	0.95
Short Long Term Debt Total	0.76		0.79	0.91	0.69	0.9	0.71	0.92	-0.8	-0.84	0.89	0.83	0.82	0.24	0.22	-0.72	0.66	0.24	0.79	-0.4	0.98	-0.76	0.77	0.86	-0.11	0.69
Other Current Liab	0.97	0.79		0.95	0.95	0.86	0.95	0.95	-0.89	-0.92	0.93	0.9	0.88	0.51	0.49	-0.96	0.91	0.75	0.84	-0.6	0.89	-0.92	0.83	0.9	-0.33	0.95
Total Current Liabilities	0.96	0.91	0.95		0.9	0.91	0.9	0.99	-0.95	-0.91	0.98	0.97	0.87	0.53	0.5	-0.93	0.91	0.6	0.79	-0.51	0.97	-0.87	0.8	0.91	-0.21	0.9
Total Stockholder Equity	0.95	0.69	0.95	0.9		0.74	0.97	0.91	-0.85	-0.82	0.94	0.85	0.78	0.72	0.7	-0.97	0.93	0.86	0.68	-0.77	0.82	-0.83	0.7	0.84	-0.54	1.0
Other Liab	0.84	0.9	0.86	0.91	0.74		0.84	0.91	-0.89	-0.97	0.88	0.88	0.97	0.21	0.18	-0.85	0.77	0.42	0.9	-0.36	0.91	-0.93	0.94	0.96	-0.09	0.74
Net Tangible Assets	0.94	0.71	0.95	0.9	0.97	0.84		0.91	-0.86	-0.91	0.92	0.85	0.9	0.57	0.54	-0.99	0.91	0.82	0.79	-0.73	0.82	-0.93	0.84	0.93	-0.51	0.97
Property Plant And Equipment Net	0.94	0.92	0.95	0.99	0.91	0.91	0.91		-0.92	-0.91	0.99	0.93	0.88	0.51	0.49	-0.92	0.88	0.6	0.81	-0.59	0.98	-0.88	0.81	0.93	-0.3	0.91
Net Debt	-0.96	-0.8	-0.89	-0.95	-0.85	-0.89	-0.86	-0.92		0.86	-0.92	-1.0	-0.82	-0.58	-0.56	0.92	-0.96	-0.62	-0.68	0.35	-0.87	0.82	-0.74	-0.85	0.05	-0.85
Retained Earnings	-0.88	-0.84	-0.92	-0.91	-0.82	-0.97	-0.91	-0.91	0.86		-0.88	-0.85	-0.99	-0.25	-0.22	0.9	-0.81	-0.56	-0.95	0.49	-0.89	0.99	-0.98	-0.98	0.24	-0.82
Accounts Payable	0.94	0.89	0.93	0.98	0.94	0.88	0.92	0.99	-0.92	-0.88		0.93	0.85	0.6	0.57	-0.94	0.9	0.64	0.75	-0.64	0.96	-0.85	0.77	0.92	-0.37	0.94
Cash	0.96	0.83	0.9	0.97	0.85	0.88	0.85	0.93	-1.0	-0.85	0.93		0.8	0.59	0.57	-0.91	0.95	0.6	0.67	-0.36	0.9	-0.8	0.72	0.84	-0.05	0.85
Non Current Assets Total	0.83	0.82	0.88	0.87	0.78	0.97	0.9	0.88	-0.82	-0.99	0.85	0.8		0.18	0.15	-0.87	0.75	0.53	0.95	-0.5	0.85	-0.99	0.99	0.98	-0.27	0.78
Non Currrent Assets Other	0.65	0.24	0.51	0.53	0.72	0.21	0.57	0.51	-0.58	-0.25	0.6	0.59	0.18		1.0	-0.63	0.73	0.76	-0.01	-0.55	0.4	-0.25	0.05	0.31	-0.41	0.72
Other Assets	0.62	0.22	0.49	0.5	0.7	0.18	0.54	0.49	-0.56	-0.22	0.57	0.57	0.15	1.0		-0.6	0.71	0.74	-0.04	-0.53	0.37	-0.22	0.02	0.28	-0.4	0.7
Long Term Debt	-0.98	-0.72	-0.96	-0.93	-0.97	-0.85	-0.99	-0.92	0.92	0.9	-0.94	-0.91	-0.87	-0.63	-0.6		-0.96	-0.83	-0.76	0.65	-0.84	0.91	-0.81	-0.91	0.41	-0.97
Cash And Short Term Investments	0.98	0.66	0.91	0.91	0.93	0.77	0.91	0.88	-0.96	-0.81	0.9	0.95	0.75	0.73	0.71	-0.96		0.82	0.61	-0.49	0.78	-0.79	0.67	0.79	-0.22	0.92
Net Receivables	0.78	0.24	0.75	0.6	0.86	0.42	0.82	0.6	-0.62	-0.56	0.64	0.6	0.53	0.76	0.74	-0.83	0.82		0.42	-0.69	0.43	-0.63	0.46	0.56	-0.57	0.86
Common Stock Shares Outstanding	0.73	0.79	0.84	0.79	0.68	0.9	0.79	0.81	-0.68	-0.95	0.75	0.67	0.95	-0.01	-0.04	-0.76	0.61	0.42		-0.44	0.81	-0.95	0.97	0.9	-0.23	0.68
Non Current Liabilities Total	-0.53	-0.4	-0.6	-0.51	-0.77	-0.36	-0.73	-0.59	0.35	0.49	-0.64	-0.36	-0.5	-0.55	-0.53	0.65	-0.49	-0.69	-0.44		-0.51	0.56	-0.44	-0.61	0.95	-0.77
Capital Lease Obligations	0.86	0.98	0.89	0.97	0.82	0.91	0.82	0.98	-0.87	-0.89	0.96	0.9	0.85	0.4	0.37	-0.84	0.78	0.43	0.81	-0.51		-0.83	0.8	0.91	-0.22	0.82
Inventory	-0.86	-0.76	-0.92	-0.87	-0.83	-0.93	-0.93	-0.88	0.82	0.99	-0.85	-0.8	-0.99	-0.25	-0.22	0.91	-0.79	-0.63	-0.95	0.56	-0.83		-0.98	-0.97	0.33	-0.83
Other Current Assets	0.76	0.77	0.83	0.8	0.7	0.94	0.84	0.81	-0.74	-0.98	0.77	0.72	0.99	0.05	0.02	-0.81	0.67	0.46	0.97	-0.44	0.8	-0.98		0.95	-0.23	0.7
Other Stockholder Equity	0.86	0.86	0.9	0.91	0.84	0.96	0.93	0.93	-0.85	-0.98	0.92	0.84	0.98	0.31	0.28	-0.91	0.79	0.56	0.9	-0.61	0.91	-0.97	0.95		-0.37	0.84
Total Liab	-0.25	-0.11	-0.33	-0.21	-0.54	-0.09	-0.51	-0.3	0.05	0.24	-0.37	-0.05	-0.27	-0.41	-0.4	0.41	-0.22	-0.57	-0.23	0.95	-0.22	0.33	-0.23	-0.37		-0.54
Net Invested Capital	0.95	0.69	0.95	0.9	1.0	0.74	0.97	0.91	-0.85	-0.82	0.94	0.85	0.78	0.72	0.7	-0.97	0.92	0.86	0.68	-0.77	0.82	-0.83	0.7	0.84	-0.54

Click cells to compare fundamentals

Recursion Pharmaceuticals Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

AVAV	AeroVironment
ELVN	Enliven Therapeutics
NFLX	Netflix

Additional Tools for Recursion Stock Analysis

When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Recursion Cash vs Total Liab Analysis

Cash vs Total Liab

Cash vs Total Liab Correlation Analysis

Correlation Coefficient

Cash

Total Liab

Recursion Pharmaceuticals fundamental ratios Correlations

Recursion Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Recursion Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Invested Capital	+ 1.0	Total Stockholder Equity
Other Assets	+ 1.0	Non Currrent Assets Other
Property Plant And Equipment Net	+ 0.99	Total Current Liabilities
Accounts Payable	+ 0.99	Property Plant And Equipment Net
Inventory	+ 0.99	Retained Earnings
Other Current Assets	+ 0.99	Non Current Assets Total

Cash	- 1.0	Net Debt
Inventory	- 0.99	Non Current Assets Total
Non Current Assets Total	- 0.99	Retained Earnings
Long Term Debt	- 0.99	Net Tangible Assets
Other Current Assets	- 0.98	Inventory
Other Stockholder Equity	- 0.98	Retained Earnings